Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study.

Arnfried U Klingbeil1, Stefan John, Markus P Schneider

  • 1Department of Medicine IV, University of Erlangen-Nürnberg, Germany.

Journal of Hypertension
|December 11, 2002
PubMed
Summary

Valsartan, an angiotensin II receptor blocker, effectively reduced the augmentation index in patients with essential hypertension. Hydrochlorothiazide lowered blood pressure but did not significantly impact this vascular function marker.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneity of Estimated GFR Slopes According to Etiology, Estimated GFR and Urinary Albumin-to-Creatinine Ratio in a Large Cohort of Patients With CKD.

Kidney international reports·2026
Same author

Predictive Value of Serum N-Terminal pro-B-Type Natriuretic Peptide and Troponin T for Incident Heart Failure: A Meta-Analysis of 9 International Cohorts.

Journal of the American Heart Association·2025
Same author

Association of Serum Afamin Concentrations With Kidney Failure in Patients With CKD: Findings From the German CKD Cohort Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2025
Same author

Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making.

Clinical kidney journal·2024
Same author

Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL-CKD.

European journal of clinical investigation·2024
Same author

Spot urinary sodium in CKD patients: correlation with 24h-excretion and evaluation of commonly used prediction equations.

BMC nephrology·2024

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Arterial hypertension involves vascular structural and functional changes.
  • Angiotensin II plays a key role in these adaptive processes.
  • Assessing vascular function markers like augmentation index is crucial in hypertension management.

Purpose of the Study:

  • To investigate the effects of angiotensin II (AT) receptor blockade on vascular function.
  • To determine if valsartan or hydrochlorothiazide (HCTZ) impacts the augmentation index in essential hypertension.

Main Methods:

  • 60 patients with essential hypertension were randomized to 6 weeks of valsartan, HCTZ, or placebo.
  • Radial artery pressure waves were measured using applanation tonometry.
  • Central aortic pressure wave and augmentation index were derived via a generalized transfer function.

Related Experiment Videos

Main Results:

  • Both valsartan and HCTZ significantly reduced systolic and diastolic blood pressure.
  • Only valsartan demonstrated a significant reduction in the augmentation index.
  • The reduction in augmentation index was significantly greater with valsartan compared to HCTZ and placebo.

Conclusions:

  • Valsartan, an AT receptor antagonist, effectively reduces the augmentation index in essential hypertension.
  • Hydrochlorothiazide lowers blood pressure but does not improve this specific vascular function marker.
  • These findings highlight differential effects of antihypertensive medications on vascular adaptation.